This is the final part of our summary of key medications released by COFEPRIS in Dec. 18, 2017. Read the first part, second, third and fourth.



These are medications that treat major clinical problems in Mexico but do not fit into any of the previous categories. This post will include treatments for diabetes type 2, hemophilia and gout and an antidepressant, among other medications.


Depression by whoismargot. CC0 Creative Commons.

Feztima, antidepressant

One person commits suicide every 40 seconds, according to the WHO. One of the conditions influencing suicidal thoughts is depression, which affects 300 million people worldwide. In Mexico, it is believed that approximately 10 million people suffer from depression, with women being the most affected with a prevalence of 10.4 percent in comparison to men’s 5.4 percent. Feztima (Levomilnacipran) is a selective serotonin-norepinephrine reuptake inhibitor used for the treatment of major depressive disorder, also known as clinical depression.


Lypaglin, treatment of type 2 diabetes

Diabetes type 2 is the first cause of death for Mexicans. This disease, closely linked to obesity, can cause irreparable damage to the kidneys, renal failure, blindness, lower extremity amputation and premature death. In 2017, 9.7 percent of Mexicans were diagnosed with type 2 diabetes, a number that is expected to continue increasing alongside national waistlines. Many diabetics also suffer from hypertriglyceridemia, a very high level of triglycerides in the blood, which is a major risk factor for cardiovascular diseases. Lypaglin (saroglitazar) can reduce both triglycerides and glucose levels in blood, as well as improving insulin resistance.


Rixubis, treatment of bleeding episodes in hemophiliacs

Hemophilia is a genetic blood coagulation disorder that impacts one out of every 5,000 men in the world. According to the Mexican Federation of Hemophilia, Mexico had a total of 6,022 registered hemophiliacs by May 2017. Hemophilia B, the second most common type after hemophilia A, is caused by a factor IX gene mutation that causes a deficiency of factor IX, a key component in blood coagulation. Rixubis (Nonacog gamma) treats factor IX deficiency and is used to control bleeding episodes in hemophiliacs. This factor is derived from a recombinant Chinese hamster ovarian cell.

By Meditations. CC0 Creative Commons.

Zurampic, treatment of gout

Also known as the “rich-man’s disease” as it was thought to be caused by consumption of large amounts of meat, gout is a form of arthritis caused by the excess accumulation of uric acid, a metabolite of purines. Uric acid is present in many tissues and normally excreted through the kidneys but it can accumulate in blood in a condition called hypeuricemia. Zurampic (lesinurad) inhibits the reabsorption of uric acid in the kidneys helping them to excrete excess. In Mexico 6.12 million people suffer from gout and, while the disease is most common in seniors, it can affect individuals at any age, although it is four times more common in men than women. Lesinurad was approved by the FDA in Dec. 22, 2015, for the treatment of hyperuricemia associated with gout.


Other medications within this package include:

  • Velphoro (Sucroferric oxyhydroxide) for chronic kidney disease
  • Ralpaxa, a combination of ibuprofen and famotidine for headaches
  • Kalbitor (Ecallantide) for the treatment of hereditary angioedema
  • Jadenu (deferasirox) for the treatment of chronic iron overload
  • Simbrinza (a suspension of brinzolamide and brimonidine tartrate) used to treat ocular hypertension
  • Duavive (bazedoxifene and conjugated estrogens) to treat moderate symptoms of menopause
  • Hemedi (propranolol), a β-blocker used to treat high blood pressure and other conditions
  • Normosang (human hemin) to treat hepatic porphyria
  • Penthromax (methoxyflurane), a general anesthetic
  • Torafen (fentanyl), a pain medication
Share →

Leave a Reply

Your email address will not be published. Required fields are marked *